Neurocysticercosis: a major cause of neurological disease worldwide.

Neurocysticercosis, which is caused by infestation of the human CNS with the tissue cysts of Taenia solium, is arguably the most common parasitic disease of the human nervous system. While most of the details of the parasite's life cycle were known by the nineteenth century and most of the clinical manifestations of T. solium infection had been identified by the mid-twentieth century, concepts regarding the prevalence of infection, associated morbidity and mortality, treatment, and epidemiology have changed dramatically over the past 10 years. The increased ease of international travel, the increasing numbers of immigrants from developing countries, and the widespread use of improved diagnostic techniques have led to widespread recognition of neurocysticercosis as a common infection not only in developing countries but also in the United States. Large case series have been reported in the southwestern United States and other areas with large immigrant populations from Latin America [2-7]. Since neurocysticercosis is not a reportable disease, the total number of cases diagnosed in the United States is not known but is estimated at >1,000 new cases each year [2], and this number appears to be increasing. While most of these cases occur in patients infected in developing countries, the number of locally acquired infections is also increasing. The ancient Greeks recognized that intestinal tapeworms were associated with ingestion of meat. They referred to the "hailstones" in meat as cysticerci, meaning bladder-tails. During the nineteenth century, Leuckart identified the complete life cycle of T. solium and noted that human cysticercosis resulted from ingestion of parasite eggs shed by tapeworm carriers. Neurocysticercosis was a frequent finding in autopsy series reported from Europe in the nineteenth century. Studies

[1]  K. O'Hoy,et al.  Vaccination against ovine cysticercosis using a defined recombinant antigen , 1989, Nature.

[2]  J. Joubert,et al.  Neurocysticercosis in 578 black epileptic patients. , 1991, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[3]  G. Román,et al.  Therapy for neurocysticercosis: a reappraisal. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Flisser,et al.  Taenia solium ocular cysticercosis: findings in 30 cases. , 1992, Annals of ophthalmology.

[5]  A. Flisser,et al.  Dipstick dot ELISA for the detection of Taenia coproantigens in humans , 1993, Parasitology.

[6]  A. Flisser,et al.  Epidemiological investigation of Taenia solium taeniasis and cysticercosis in a rural village of Michoacan state, Mexico. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[7]  J. A. Brand,et al.  An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). , 1989, The Journal of infectious diseases.

[8]  A. White,et al.  Effects of serum from neurocysticercosis patients on the structure and viability of Taenia solium oncospheres. , 1993, The Journal of parasitology.

[9]  C. Filley,et al.  Neurocysticercosis in the United States: 35 cases and a review. , 1987, Reviews of infectious diseases.

[10]  A. Flisser,et al.  Neurocysticercosis in an Orthodox Jewish community in New York City. , 1992, The New England journal of medicine.

[11]  V. Rajshekhar Etiology and management of single small CT lesions in patients with seizures: understanding a controversy , 1991, Acta neurologica Scandinavica.

[12]  Z. Jiang,et al.  Nationwide survey of human parasite in China. , 1994, The Southeast Asian journal of tropical medicine and public health.

[13]  T. Crawford,et al.  Intraparenchymal cerebral cysticercosis in children: diagnosis and treatment. , 1988, Pediatrics.

[14]  R. Gilman,et al.  The marketing of cysticercotic pigs in the Sierra of Peru. The Cysticercosis Working Group in Peru. , 1993, Bulletin of the World Health Organization.

[15]  T. Govezensky,et al.  Immunodiagnosis of neurocysticercosis. Disappointing performance of serology (enzyme-linked immunosorbent assay) in an unbiased sample of neurological patients. , 1992, Archives of neurology.

[16]  Relationship Between Epilepsy and Tropical Diseases , 1994 .

[17]  S. Waterman,et al.  Cysticercosis surveillance: locally acquired and travel-related infections and detection of intestinal tapeworm carriers in Los Angeles County. , 1992, The American journal of tropical medicine and hygiene.

[18]  H. R. Martinez,et al.  Medical and surgical treatment in neurocysticercosis a magnetic resonance study of 161 cases , 1995, Journal of the Neurological Sciences.

[19]  R. J. Otto,et al.  MR imaging of neurocysticercosis. , 1989, AJR. American journal of roentgenology.

[20]  A de Aluja,et al.  The histopathology of porcine cysticercosis. , 1988, Veterinary parasitology.

[21]  O. D. Del Brutto Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patientswith neurocysticercosis , 1994, Neurology.

[22]  C. Suquet,et al.  Parasite defense mechanisms for evasion of host attack; a review. , 1987, Veterinary parasitology.

[23]  O. D. Brutto Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patientswith neurocysticercosis , 1994 .

[24]  F. Rubio-Donnadieu,et al.  Praziquantel in the treatment of neurocysticercosis , 1985, Neurology.

[25]  G. Mitchell,et al.  Stage‐specific immunity to Taenia taeniaeformis infection in mice. A histological study of the course of infection in mice vaccinated with either oncosphere or metacestode antigens , 1990, Parasite immunology.

[26]  D. McManus,et al.  An IgG (Fcγ,)-binding protein of Taenia crassiceps (Cestoda) exhibits sequence homology and antigenic similarity with schistosome paramyosin , 1993, Parasitology.

[27]  A. White,et al.  Extraparenchymal neurocysticercosis: report of five cases and review of management. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  P. Preux,et al.  Headache and Cysticercosis in Ecuador, South America , 1995, Headache.

[29]  O. D. Brutto Cysticercosis and cerebrovascular disease: a review. , 1992 .

[30]  R. Bryan,et al.  Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. , 1991, The Journal of infectious diseases.

[31]  R. Gilman,et al.  Epidemiology of taeniasis and cysticercosis in a Peruvian village. The Cysticercosis Working Group in Peru. , 1992, American journal of epidemiology.

[32]  E. Love,et al.  Surveillance and Control Programs for Cestode Diseases , 1989 .

[33]  J. Sotelo,et al.  A new shunt for hydrocephalus that relies on CSF production rather than on ventricular pressure: initial clinical experiences. , 1995, Surgical neurology.

[34]  J. Goding,et al.  Studies on immune responses to larval cestodes in mice. Increased susceptibility of certain mouse strains and hypothymic mice to Taenia taeniaeformis and analysis of passive transfer of resistance with serum. , 1977, The Australian journal of experimental biology and medical science.

[35]  A. White,et al.  Asymptomatic neurocysticercosis in a patient with AIDS and cryptococcal meningitis. , 1995, American Journal of Medicine.

[36]  S. Geerts Cysticercosis in Africa. , 1995, Parasitology today.

[37]  D. Mendonça,et al.  Spectrum of epilepsy in neurocysticercosis: a long‐term follow‐up of 143 patients , 1995, Acta neurologica Scandinavica.

[38]  McCormick Gf Cysticercosis--review of 230 patients. , 1985 .

[39]  A. Jena,et al.  MRI (magnetic resonance imaging) spectrum of epilepsy. , 1994, Journal of the Indian Medical Association.

[40]  C. Suquet,et al.  Isolation and partial characterization of a Taenia taeniaeformis metacestode proteinase inhibitor. , 1984, International journal for parasitology.

[41]  M. Cruz,et al.  Potential eradicability of taeniasis and cysticercosis. , 1993, Bulletin of the Pan American Health Organization.

[42]  H. Dixon,et al.  Cysticercosis , 1962, Neurology.

[43]  F. Dabis,et al.  Epidemiological study of neuro-cysticercosis in northern Togo (West Africa). , 1989, Acta Leidensia.

[44]  A. Flisser Neurocysticercosis in Mexico. , 1988, Parasitology today.

[45]  M. Cruz,et al.  Operational studies on the control of Taenia solium taeniasis/cysticercosis in Ecuador. , 1989, Bulletin of the World Health Organization.

[46]  A. Mirsky,et al.  Neurocysticercosis and performance on neuropsychologic tests: a family study in Ecuador. , 1995, The American journal of tropical medicine and hygiene.

[47]  D. D. Heath,et al.  Taenia ovis recombinant vaccine – ‘quo vadit’ , 1995, Parasitology.

[48]  G. Locke,et al.  Cerebral cysticercosis: documentation of natural history with CT. , 1989, Radiology.

[49]  B. Estañol,et al.  Mechanisms of hydrocephalus in cerebral cysticercosis: implications for therapy. , 1983, Neurosurgery.

[50]  M. Cruz,et al.  Albendazole versus praziquantel in the treatment of cerebral cysticercosis: clinical evaluation. , 1991, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[51]  Xiao Zx,et al.  [Cysticercosis of the central nervous system--a clinical study of 1,400 cases]. , 1988 .

[52]  M. T. Medina,et al.  Neurocysticercosis as the main cause of late-onset epilepsy in Mexico. , 1990, Archives of internal medicine.

[53]  J. Sotelo,et al.  Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. , 1987, Journal of neurosurgery.

[54]  R. Norman,et al.  Cerebral cysticercosis treated biphasically with dexamethasone and praziquantel. , 1983, Annals of internal medicine.

[55]  J. Seidel Diagnostic Pathology of Parasitic Infection with Clinical Correlation , 1991 .

[56]  G. McCormick Cysticercosis--review of 230 patients. , 1985, Bulletin of clinical neurosciences.

[57]  W. Shandera,et al.  Neurocysticercosis in Houston, Texas: A Report of 112 Cases , 1994, Medicine.

[58]  M. Behari,et al.  Albendazole in neurocysticercosis. , 1995, The National medical journal of India.

[59]  R. Gilman,et al.  Factors associated with Taenia solium cysticercosis: analysis of nine hundred forty-six Peruvian neurologic patients. Cysticercosis Working Group in Peru (CWG). , 1995, The American journal of tropical medicine and hygiene.

[60]  R. Kuhn,et al.  Mice infected with the larvae of Taenia crassiceps exhibit a Th2-like immune response with concomitant anergy and downregulation of Th1-associated phenomena , 1996, Parasitology.

[61]  A. Carpio,et al.  A Proposal for Classification of Neurocysticercosis , 1994, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[62]  W. Hauser,et al.  Is the course of neurocysticercosis modified by treatment with antihelminthic agents? , 1997, Archives of internal medicine.

[63]  A. Flisser,et al.  Community-based epidemiological investigations of cysticercosis due to Taenia solium: comparison of serological screening tests and clinical findings in two populations in Mexico. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  A. Flisser,et al.  Cysticercosis: present state of knowledge and perspectives. , 1982 .

[65]  C. Cantú,et al.  Cerebrovascular complications of neurocysticercosis. Clinical and neuroimaging spectrum. , 1996, Archives of neurology.

[66]  C. Shoemaker,et al.  Paramyosin inhibits complement C1. , 1992, Journal of immunology.

[67]  F. Rubio-Donnadieu,et al.  Therapy of parenchymal brain cysticercosis with praziquantel. , 1984, The New England journal of medicine.

[68]  J. Sotelo,et al.  Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial. , 1988, Archives of neurology.

[69]  S. Shulman,et al.  Neurocysticercosis among children in Chicago. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  D. Bikin,et al.  Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. , 1994, The Journal of infectious diseases.

[71]  M. Hay,et al.  Seizures and neurocysticercosis in black men. , 1992, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[72]  A. White,et al.  Host-parasite interactions in Taenia solium cysticercosis. , 1992, Infectious agents and disease.

[73]  P. Bittencourt,et al.  High-dose praziquantel for neurocysticercosis: efficacy and tolerability. , 1990, European neurology.

[74]  G. Trenholme Discrepancies Between Cerebral Computed Tomography and Western Blot in the Diagnosis of Neurocysticercosis , 1994 .

[75]  J. Sotelo,et al.  The course of seizures after treatment for cerebral cysticercosis. , 1992, The New England journal of medicine.

[76]  A. Hightower,et al.  Seroprevalence of cysticercosis in an Orthodox Jewish community. , 1995, The American journal of tropical medicine and hygiene.

[77]  H. García,et al.  Diagnosis of cysticercosis in endemic regions , 1991, The Lancet.

[78]  A. White,et al.  Taenia solium cysticercosis: host-parasite interactions and the immune response. , 1997, Chemical immunology.

[79]  M L Apuzzo,et al.  Surgical considerations in treatment of intraventricular cysticercosis. An analysis of 45 cases. , 1984, Journal of neurosurgery.

[80]  C. Zee,et al.  MRI of Intraventricular Cysticercosis: Surgical Implications , 1993, Journal of computer assisted tomography.

[81]  V. Tsang,et al.  Taenia solium cysticercosis: An under-recognized but serious publica health problem , 1995 .

[82]  R. Rangel,et al.  Cysticercotic encephalitis: a severe form in young females. , 1987, The American journal of tropical medicine and hygiene.